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Identification of a novel Fca receptor expressed by human of the IgA1 subclass [5, 6] in the glomerular mesangium.
mesangial cells. Berger and Hinglais published the first description of
Background. IgA nephropathy (IgAN) is characterized by IgAN in 1968 [7], but the mechanisms of IgA depositionmesangial deposits of polymeric IgA (pIgA). The pathological
and the consequent initiation of glomerular injury re-consequences of IgA deposition are believed to center on direct
main unknown [8, 9]. There is no evidence to suggest thatinteraction between IgA and the glomerular mesangial cell
(MC). We have characterized a novel mesangial receptor that the deposited IgA is directed against specific glomerular
recognizes the Fc portion of IgA. antigens, either endogenous or deposited [9], and al-
Methods. Five primary MC cultures were evaluated for IgA though there is often co-deposition of IgG and C3 [10],binding by flow cytometry, and specificity of binding was deter-
there is little evidence for widespread activation of themined by competitive inhibition. Relative affinities of the re-
complement system [11] or of a dominant mononuclearceptor for all IgA isoforms were also determined, and binding
of pIgA1 was compared to monomer. The identified Fc recep- inflammatory cell infiltrate [12], except in the rare instance
tor was then compared with CD89, hitherto the only other Fca of crescentic IgAN [13]. The deposition of IgA and the
receptor reported. CD89 protein and mRNA expression were subsequent glomerular injury appear therefore to bedetected by conventional and intracellular flow cytometry, se-
phenomena focused on the IgA molecule itself ratherquencing of reverse transcription-polymerase chain reaction
than on the recruitment of other arms of the immune(RT-PCR) products, and Northern blotting.
Results. All MCs constitutively expressed a receptor that system. This has focused attention on direct interactions
bound IgA in an Fca-dependent fashion. The receptor recog- between the deposited IgA, the mesangial matrix, and
nized secretory and serum IgA1 and IgA2 equally, but pIgA the mesangial cell (MC).bound with much greater affinity than monomer. At no time
Mesangial cells in vitro are known to bind IgA [14–16],were we able to detect CD89 synthesis, although three novel
CD89-related mRNA transcripts were identified by RT-PCR. and this can trigger a number of events, principally en-
Conclusions. We have clearly demonstrated that MCs con- hanced proliferation [16, 17], cytokine release [15–17],
sistently express an FcaR distinct from the myeloid FcaR and extracellular matrix production [18]. Therefore, MCs
CD89. This novel receptor binds pIgA with high affinity and
might be expected to express functional IgA receptors,may therefore mediate the mesangial injury that follows IgA
the ligation of which may explain some of the pathologi-deposition in IgAN. While immunogenically distinct, the mes-
angial Fca receptor may share some molecular homology with cal changes seen in IgAN. MC activation through IgA
CD89, as mRNA transcripts with partial identity to CD89 were binding might underlie the mesangial proliferation and
found in all five MC cultures. extracellular matrix expansion characteristic of IgAN,
while impaired clearance of nephritogenic IgA from the
glomerulus might occur if in IgAN the deposited IgA
IgA nephropathy (IgAN) is the most common glomer- failed to interact normally with MC receptors. A clearer
ulonephritis in the Western world, leading to progressive understanding of the nature of MC IgA receptors is
renal failure in almost one third of the cases [1, 2]. It is therefore of paramount importance.
characterized by deposition of polymeric IgA (pIgA) [3, 4] Currently, three different classes of IgA receptor have
been characterized in detail: the hepatic asialoglycopro-
tein receptor (ASGPR) [19, 20], which recognizes theKey words: Fca receptor, CD89, IgA nephropathy, human mesangial
cells. asialyl glycan moieties of many glycoproteins, including
IgA1, and is expressed mainly by the liver; the polymericReceived for publication January 28, 1999
immunoglobulin receptor [21, 22], which binds J-chain–and in revised form October 18, 1999
Accepted for publication November 24, 1999 containing immunoglobulins (IgA and IgM) and is found
predominantly in the mucosae; and FcaR1 (CD89)Ó 2000 by the International Society of Nephrology
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[23, 24], which is specific for IgA, binding the constant mologous system incorporating human IgA and HMC
only. The IgA receptor identified proved to be an FcaRregion of the a-heavy chain of IgA1 and IgA2 and ex-
pressed by cells of myeloid lineage. The existence of capable of binding all isoforms of IgA but with particular
affinity for pIgA. In view of previous reports that MCsother IgA receptors is recognized: T and B lymphocytes
[25–27] and natural killer cells [28] express IgA receptors express CD89, we went on to demonstrate that the mes-
angial receptor was not CD89 but a novel FcaR, althoughdistinct from those already mentioned, but these have
yet to be isolated. Changes in the expression of CD89 the two proteins may share common molecular origins.
have been reported in IgAN [29–32]. Two early studies
reported increased expression of CD89 on both periph-
METHODS
eral monocytes [29] and neutrophils [30] in IgAN, but
Materialsmore recent work indicates down-regulation of CD89
on monocytes and neutrophils in IgAN [31]. Reduced Unless stated otherwise, all reagents were purchased
from Sigma-Aldrich Chemical Co. (Dorset, UK). For theCD89 expression may impair systemic IgA clearance,
contributing to the high circulating levels of IgA charac- characterization of purified human MCs (HMCs), indi-
rect immunohistochemistry was performed for myosin,teristic of IgAN [31, 32]. There is also evidence that post-
translational modification of CD89 in IgAN results in actin, vimentin, desmin, fibronectin, CD45, cytokeratin,
and factor VIII-related antigen (all Dako Ltd., Ely, UK).enhanced binding of IgA to these cells, and this may be
responsible for the down-regulation of CD89 described IgA binding was assessed using FITC-conjugated human
IgA1 (3.0 mol FITC per mole IgA), which was .90%[31]. Intriguingly, from the same study, it was also noted
that there was a greater likelihood of mesangial prolifer- polymeric (Jackson ImmunoResearch Laboratories, West-
grove, PA, USA). Unconjugated IgA, IgG (Jackson Im-ation and glomerular sclerosis in patients with IgAN if
their circulating monocytes bound more IgA. It is not munoResearch Laboratories), IgM, and asialofetuin were
used in evaluating specificity of IgA binding to HMCs.yet known how this mechanism might operate, but it is
clear that changes in the IgA–receptor interaction may The following monoclonal antibodies (MoAb) were used
to detect CD89: A3 (IgG1k), A59 (IgG1k), A62 (IgG1k),have important implications in the pathogenesis of mes-
angial injury in IgAN, especially if such effects were to A77 (IgG1k), all of which are kind gifts from Dr. R.C.
Monteiro (Necker Hospital, Paris, France), and My43be seen occurring between deposited IgA and mesangial
IgA receptors. (IgMk) was kindly provided by Dr. L. Shen (Dartmouth
Medical School, Hanover, NH, USA). As positive con-Unfortunately, much of the information concerning
the expression of IgA receptors by MC is confusing and trols for mesangial surface staining, anti-human lympho-
cyte antigen (anti-HLA) class I (IgG1k) and, followingcontradictory. While some studies have reported expres-
sion of the hepatic ASGPR [33] and CD89 [14, 34, 35] activation, anti-HLA class II (IgG2a) were used. Controls
for intracellular flow cytometry were rabbit FITC-F(ab9)2by MCs, others have been unable to confirm this (ab-
stract; Lai et al, J Am Soc Nephrol 9:535, 1998) [36]. In antilactoferrin (Jackson ImmunoResearch Laboratories),
antimitochondria (IgG1k), antinucleus (IgMk), and anti-part, these discrepancies stem from the heterologous
systems employed in the different studies. Human, rat, golgi zone (IgG1k) antibodies (Chemicon International
Inc., Temecula, CA, USA). Unconjugated MoAbs andand mouse IgA have all been used, and in most cases,
the bound IgA has been heat aggregated. Binding has IgA isoforms were detected using rabbit FITC-F(ab9)2
antimouse Igs and rabbit FITC-F(ab9)2 antihuman IgAathen been studied using primary cultures of either rat
MCs, HMCs, or both. Interpretation of such studies is chains (Dako Ltd.), respectively. As irrelevant controls
antihuman cytokeratin 8 (IgMk), mouse IgG1k, and anti-difficult, particularly if one is looking for the expression
of specific receptors by HMCs. This is exemplified by human cytokeratin (IgG1k) were used (Dako Ltd.). For
the detection of MoAb in HMC characterization andthe initial studies looking for FcgR expression by MCs.
The first published reports, which had used predomi- immunoblotting of cell lysates, an alkaline phosphatase-
conjugated rabbit antimouse Igs (Dako Ltd.) was used.nantly rat MCs, demonstrated constitutive expression of
an FcgR analogous to human FcgRII [37, 38]. However,
Purification of IgA isoforms and preparation ofHMC FcgR expression only occurs after prolonged stim-
IgA1 fragmentsulation with interferon-g and bacterial lipopolysaccha-
ride (LPS), and then the FcgR expressed resembles Serum IgA1 and IgA2 were prepared as described
previously [40]. Briefly, serum was precipitated with anFcgRIII more closely than FcgRII [39]. Such discrepanc-
ies between rat and HMCs may also partly explain the equal volume of 50% ammonium sulfate followed by
gel filtration on a Sepharose 6B column (Pharmacia,contradictory reports in the literature concerning the
expression of mesangial IgA receptors. Uppsala, Sweden). IgA was then isolated from the pro-
tein peak by anion exchange chromatography on aTherefore, the purpose of this study was to identify
and characterize the mesangial IgA receptor using a ho- DEAE-Sephacel column (Pharmacia) equilibrated in 50
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mmol/L Tris/HCl, pH 8.0. IgA was eluted from the col- Cells
umn with a linear salt gradient 0 to 0.5 mol/L NaCl in Primary cultures of HMCs were cultured from glomer-
the same buffer. IgA containing fractions, as determined uli according to a method described previously [44].
by radial immunodiffusion (RID), were pooled, and Briefly, renal cortex was obtained from the normal portion
IgA1 was purified by affinity chromatography on Jacalin- of nephrectomy specimens removed for circumscribed
Agarose (Vector Laboratories, Peterborough, UK) [41]. carcinoma. Glomeruli were isolated from the minced tis-
Unbound proteins were removed by extensive washing sue by sequential sieving through 150, 100, and 80 mesh
of the Jacalin-Agarose with 0.175 mol/L Tris HCl buffer, screens. The retained glomeruli were then incubated at
pH 7.5, and IgA1 eluted from the jacalin with 1 mol/L room temperature (RT) for one hour with 500 U/mL
galactose in Tris HCl. The IgA1 was then dialyzed collagenase (type IV) before being resuspended in RPMI
1640 with 25 mmol/L HEPES supplemented with 100against phosphate buffered saline (PBS) and stored in
U/mL penicillin, 100 mg/mL streptomycin, 2 mmol/Laliquots at 2208C until required. The purity of isolated
l-glutamine, 25 mmol/L sodium bicarbonate (all LifeIgA1 (.95%) was evaluated by sodium dodecyl sulfate-
Technologies, Paisley, UK), 5 mg/mL human transferrin,polyacrylamide gel electrophoresis (SDS-PAGE). The
5 mg/mL bovine insulin, 5 ng/mL sodium selenite, andeffluent from the Jacalin-Agarose contained IgA2 with
20% heat-inactivated fetal calf serum (HIFCS). Glomer-a small amount of IgG contamination, which was re-
uli were cultured in untreated 75 cm2 flasks (Costar,moved by passage through a protein G-Sepharose affin-
Cambridge, MA, USA) and maintained in humidifiedity column prior to cation-exchange chromatography on
5% CO2 atmosphere at 378C. Under such conditions,an HR 5/5 FPLC mono S column (Pharmacia). Bound
HMCs outgrew from the glomeruli after 7 to 14 daysproteins were eluted on a linear gradient 0 to 0.5 mol/L
in culture, reaching confluence by day 21. HMCs wereNaCl in 50 mmol/L sodium acetate. The IgA2 eluted
purified by successive subcultures and passaged whenwas found to contain only minor contaminants by SDS-
confluent using either 0.05% trypsin-0.02% ethylenedi-PAGE.
aminetetraacetic acid (EDTA; Life Technologies) or 1Secretory IgA was purified from human colostrum
mmol/L EDTA alone. HMC cultures were homogenoususing a combination of gel filtration on Sepharose 6B
after four to five weeks of subculture and were morpho-followed by anion-exchange chromatography on DEAE-
logically characterized by phase contrast microscopy;Sephacel, as previously described [42]. Secretory IgA1
there was positive staining for the intermediate filamentsand IgA2 were then separated by affinity chromatogra-
desmin and vimentin, intracellular actin and myosin andphy on Jacalin-Agarose, as detailed previously in this
cell surface fibronectin. Immunostaining was negativearticle.
for factor VIII-related antigen and cytokeratin excludingMonomeric and polymeric forms of IgA1 were pre-
endothelial and epithelial contamination, respectively.
pared from the plasma of a patient with an IgA1k my-
All experiments were performed on confluent HMCs
eloma, which had been shown to be 50% polymer. IgA1 between passages 5 to 9. In an attempt to induce IgA
was purified from ammonium sulfate precipitates using receptor expression, some HMCs were stimulated with
Jacalin-Agarose as previously described. This affinity- varying concentrations of phorbol 12-myristate 13-acetate
purified IgA1 was then separated into monomer and (PMA), LPS (isolated from E. coli), interferon-g (IFN-g),
polymer by gel filtration chromatography using a Super- tumor necrosis factor-a (TNF-a), or interleukin-6 (IL-6).
dex 200 preparative column (Pharmacia). The separated For these experiments, HMCs were allowed to grow to
monomeric IgA (mIgA) and pIgA were free of contami- confluence and were then rendered quiescent in medium
nants by SDS-PAGE. containing 0.5% HIFCS for 72 hours prior to incubation
Serum IgA1 Fc and Fab fragments were prepared us- for 48 hours in test medium.
ing a crude IgA1 protease preparation from Clostridium The human monocytic cell line U937 (CRL 1593) was
ramosum (a kind gift from Prof. M. Kilian, Department obtained from ATCC (Rockville, MD, USA) and main-
of Medical Microbiology and Immunology, University of tained in RPMI 1640 with 2 mmol/L l-glutamine, 100
Aarhus, Denmark) according to a previously published U/mL penicillin, 100 mg/mL streptomycin, and 10%
method [43]. The IgA1 protease was incubated for 36 HIFCS. Cells were incubated in a fully humidified air
hours at 378C with affinity-purified IgA1, and the resul- atmosphere containing 5% CO2 at 378C. To induce CD89
tant Fc and Fab fragments were then separated by gel expression, cells were stimulated for 72 hours with 1027
filtration on a Superose 6 (HR 16/60) column (Pharmacia). mol/L PMA.
The identities of the Fc and Fab fragments were con-
Immunofluorescence and flow cytometryfirmed by enzyme-linked immunosorbent assay (ELISA)
using rabbit antihuman IgAa chain-specific antibodies and Confluent HMCs were detached either with trypsin/
EDTA or EDTA alone and washed in PBS containingrabbit antihuman Ig light chain antibodies (Dako Ltd.).
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0.1% bovine serum albumin (BSA) and 0.05% sodium GmbH, Vienna, Austria). During permeabilization, cells
were incubated in triplicate with 20 mL of anti-CD89azide (P/B/A). Cells (1 3 106) were then incubated in
triplicate for one hour at 48C with 50 mL of P/B/A alone MoAb, isotype control, or a positive MoAb control, at
previously optimized dilutions, for 15 minutes at RT.or containing one of the human IgA preparations, at
final concentrations varying between 0.001 and 5.0 mg/mL. After washing twice in 5 mL of P/B/A, cells were resus-
pended in 50 mL of rabbit FITC-F(ab9)2 antimouse IgsAfter two washes in ice-cold P/B/A, cells not incubated
with IgA-FITC were resuspended for one hour at 48C for 30 minutes at RT. Following two further washes,
cells were resuspended in 300 mL of P/B/A, and cell-in rabbit FITC-F(ab9)2 antihuman IgAa chain. After an
additional wash in ice-cold P/B/A, all cells were incu- associated fluorescence was measured by flow cytometry
as previously described. Nonspecific binding was esti-bated for two minutes in P/B/A containing propidium
iodide (5 mg/mL) before a final wash and resuspension mated by incubating permeabilized cells with irrelevant
IgG1k and IgMk control antibodies, and the measuredin 300 mL of P/B/A at 48C. Cell-associated fluorescence
intensity was then evaluated by flow cytometry with a fluorescence was then subtracted from the MCF to give
the specific intracellular staining for each MoAb. AsFACScan flow cytometer coupled to LYSIS II software
(Becton Dickinson, San Jose, CA, USA). Dead cells some Ig receptors can also exist as soluble secreted iso-
forms, we wanted to ensure that we did not miss such awere gated out by propidium iodide staining, and a mini-
mum of 104 cells were analyzed. Data are expressed variant form of CD89. Tissue culture supernatants from
quiescent and activated HMCs were collected, concen-either as arbitrary units of median channel fluoresence
(MCF) intensity, where the IgA was unconjugated or trated, and resolved by 10% SDS-PAGE before being
immunoblotted with an anti-CD89 MoAb (A3). Finally,a MoAb was used, or molecules of equivalent soluble
fluorescein (MESF) when IgA-FITC was used. To stan- in an attempt to induce latent CD89 expression, HMCs
were pretreated with a range cytokines, and both celldardize cell-associated immunofluorescence between
different experiments, the FACScan was calibrated with surface and intracellular staining were repeated. Induc-
tion of HLA class II and increased HLA class I expres-quantitative fluorescein microbead standards (Becton
Dickinson). A linear regression analysis of mean fluo- sion were used as markers of HMC activation. For com-
parison, nonpermeabilized cells and CD89-expressingrescence intensity versus fluorescein molecules per parti-
cle was performed on the bead values, and the resulting PMA-activated U937 cells were used as controls for all
of these experiments.formula was used to determine MESF [45].
The ability of human Igs (IgM, IgG, IgA), IgA frag-
SDS-PAGE and immunoblottingments (Fc and Fab), and asialofetuin, a ligand with high
affinity for the hepatic ASGPR, to block IgA binding to To confirm the flow cytometry data, HMC lysates were
prepared from confluent monolayers, and the extractedHMCs was determined by adding various concentrations
of “blocking” proteins for 45 minutes at 48C before incu- proteins were immunoblotted and probed for the pres-
ence of CD89. To detect possible soluble isoforms ofbating with IgA-FITC (50 mg/mL). BSA was also used
as an unrelated inhibitor. CD89, the respective culture supernatants were also col-
lected, concentrated 35 by vacuum centrifugation at RT
Detection of CD89 protein synthesis by human and were similarly immunoblotted and probed. Briefly,
mesangial cells following removal of tissue culture supernatants, cells
were washed with PBS, scraped into 1% Nonidet P-40For the detection of cell surface CD89, HMCs were
washed twice with P/B/A and incubated in triplicate for (NP-40; Merck Ltd., Dorset, UK) in wash buffer (PBS
containing 0.3 mol/L NaCl and 1% Tween 20), and thenone hour at 48C with 50 mL of appropriately diluted anti-
CD89 MoAb or an equal amount of isotype-matched incubated at RT for 30 minutes. The cell scrapings were
then transferred into 2 mL tubes and sonicated for 5mouse antibodies to determine nonspecific background
binding. HMCs were washed and then incubated with seconds using a Jencons 50 W sonicator and centrifuged
for 30 seconds at 11,600 3 g. Sonication and centrifuga-rabbit FITC-F(ab9)2 antimouse Igs for one hour at 48C.
After further washing, HMCs were stained with propid- tion were repeated, and the lysate supernatants were
assayed for total protein content using a commercialium iodide before being resuspended in 300 mL of P/B/A
and analyzed by flow cytometry. In addition, HMCs were BioRad DC protein assay using BSA standards (Bio-
Rad Laboratories, Richmond, CA, USA). HMC lysatespreincubated with My43 in an attempt to block mesan-
gial IgA binding. Intracellular flow cytometry was also and culture supernatants (500 mg protein/lane) were then
resolved by SDS-PAGE under nonreducing conditionsperformed to identify cytoplasmic CD89, which had not
been expressed on the MC surface. For this, cells were in a Laemmli system [46]. Proteins were visualized with
Coomassie Brilliant Blue R-250 (0.5% in 40% methanol/collected, as per surface staining, before being fixed and
the cell membrane permeabilized using a commercially 10% acetic acid). Following electrophoresis, the proteins
were transferred onto nitrocellulose membranes, and im-available kit (Fix-&-Perm; An der Grub Bio Research
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munoblotting was carried out according to Towbin,
Staehelin, and Gordon [47]. Nitrocellulose membranes
were blocked for two hours at RT in 2% BSA/wash
buffer to avoid nonspecific fixation. After extensive
washing with TBS/0.1% Tween 20 (TTBS), membranes
were incubated for two hours at RT with either anti-
CD89 or control MoAb diluted in TTBS. After removal
of excess antibody by vigorous washing with TTBS, spe-
cific antibody binding was detected using alkaline phos-
phatase-conjugated rabbit antimouse Igs. The blots were
developed using 5-bromo-4-chloro-3-indoyl phosphate
(BCIP).
Detection of CD89 mRNA expression by RT-PCR,
sequencing, and Northern blotting
Total RNA was extracted from HMCs and PMA-acti-
vated U937 cells using TRIzol reagent (Life Technolo-
gies). cDNA was synthesized from equal amounts of total
RNA with avian myeloblastosis virus (AMV) reverse tran-
scriptase (Promega, Southampton, UK). CD89 transcripts
were directly amplified on a Techne Genius Thermocycler
using Thermolyticus aquaticus (Taq) DNA polymerase Fig. 1. IgA binding to cultured human mesangial cells (HMCs). Cells
were detached and washed in PBS/BSA/sodium azide (P/B/A) before(Promega) and combinations of selected primers encom-
being incubated for one hour at 48C with a range of IgA-FITC concen-passing the entire CD89 coding region [#1, sense, 59-ATG
trations. Mesangial IgA binding is presented as molecules of equivalent
GAC CCC AAA CAG ACC (S1); #2, sense, 59-CCA soluble fluorescein (MESF) 6 SEM and corresponds to five separate
experiments each performed in triplicate on a single HMC cell line.TGC CTT TCA TAT CTG CC (EC1); #3, sense, 59-ACA
IgA binding was concentration dependent and saturation was achievedTGG ACG CAA ACA AGG (EC1); #4, antisense,
at 50 mg/mL of IgA-FITC. Similar results were obtained with each of
59-TGT GCC AAT TTT CAA CCA G (TM/C); #5, the other four HMC lines.
antisense, 59-CTT GCA GAC ACT TGG TGT TC
(TM/C); #6, antisense, 59-TCC AGG TGT TTA CTT
GCA GAC AC (TM/C)] [48] or as an internal control, also performed. Briefly, 30 mg aliquots of RNA were
GAPDH (sense, 59-ACC ACA GTC CAT GCC ATC electrophoresed on a 1% agarose gel containing 1.9%
CAC, and antisense, 59-TCC ACC ACC CTG TTG CTG formaldehyde, in MOPS buffer [3-(N-morpholino)pro-
TA). In order to detect the novel CD89 isoform, FcaRb pane-sulfonic acid] and transferred on to Hybond-N ny-
[49], each of the CD89-specific forward primers were lon membranes (Amersham Life Science Ltd., Bucking-
also combined with reverse primers specific for the novel hamshire, UK), as described [50]. Hybridization was
39 coding sequence (#A, 59-GTG CAC GTC TTC ATA performed overnight at 428C using a 32P-dCTP–labeled
TTC CTG CC; #B, CTG GAC AGC CAA CCC AGA cDNA probe generated from U937 cells by RT-PCR
CAC AGG). The amplification profile involved 30 cycles using #1 and #6. This 874 bp fragment encompasses the
of denaturation at 918C for one minute, primer annealing whole of the translated CD89 transcript, and its sequence
at 608C for one minute, and primer extension at 728C was confirmed prior to use. Following stringency washes,
for two minutes. The PCR products were resolved by membranes were exposed to X-OMAT AR film (East-
2% agarose gel electrophoresis and validated by the pre- man Kodak Co., Rochester, NY, USA) with intensifier
dicted size and sequence analysis. For sequencing, se- screens at 708C for two to six days before developing.
lected bands were purified from the gel using the Sepha- Control hybridization for equal loading was performed,
glase BandPrep kit (Pharmacia) and DNA synthesized using a radiolabeled cDNA probe for cyclophilin (Smith-
from the purified cDNA using the ABI PRISMe dRho- kline Beecham Pharmaceuticals, King of Prussia, PA,
damine Terminator Cycle Sequencing Ready Reaction USA).
Kit (Perkin Elmer, Beaconsfield, UK). The extension
products were then precipitated with ethanol, separated
RESULTSby 6% denaturing polyacrylamide gel electrophoresis,
Binding characteristics of IgA to humanand analyzed using an automated sequencer (Perkin
mesangial cellsElmer).
Northern blot analysis of RNA from both quiescent IgA binding to HMCs was dose dependent, and satura-
tion was achieved at approximately 50 mg/mL (Fig. 1).and activated MCs and PMA-activated U937 cells was
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Fig. 2. Determination of the specificity of IgA binding to cultured Fig. 3. Binding of different IgA isoforms to HMCs. Equal numbers of
HMCs. Mesangial cells were detached, washed, and incubated for 45 cells were incubated for 60 minutes at 48C with 1 mg/mL of each IgA
minutes at 48C with an excess of unlabelled inhibitor protein before isoform, except mIgA1 (2.0 mg/mL) and binding detected with a FITC-
assessment of binding with IgA-FITC (50 mg/mL). Data are expressed F(ab9)2 antihuman IgAa chain antibody. Data represent the MCF 6
as the percentage inhibition produced by each inhibitor protein com- SEM of four different experiments using the same HMC line. HMCs
pared with binding of IgA-FITC in the absence of inhibitor. Results were capable of binding all isoforms of IgA equally; however, pIgA
shown are means 6 SEM of four different experiments performed on bound with a much greater affinity than any other IgA isoform. These
a single HMC line. No inhibition was seen with BSA, IgG, IgM, IgA findings were consistent across the five different primary mesangial cell
Fab fragment, or ASF. Only intact IgA and Fca fragment were able cultures.
to inhibit the binding of IgA to HMC, and this was consistently seen
with all five primary HMC cultures.
forms to bind to HMCs. As shown in Figure 3, HMCs
bound all isoforms of human IgA, and there was no
Similar results were obtained with HMCs from each of difference in the binding of secretory or serum IgA1 and
five established primary HMC cultures. IgA binding was IgA2. A direct comparison between pIgA1 and mIgA1
unaffected by the method of cell detachment (data not binding revealed that, although the mesangial FcaR has
shown). To determine the specificity of this binding, we a relatively low affinity for mIgA1 (appreciable surface
evaluated the ability of different unlabeled proteins to IgA staining was only seen when 2 mg/mL of mIgA1
inhibit binding of 50 mg/mL of IgA-FITC to HMCs (Fig. was used), the receptor had a much greater affinity for
2). There was little inhibition with either BSA (2 mg/mL), pIgA1; this was consistent for all five mesangial culture
the alternative human Igs (IgG 4 mg/mL and IgM lines.
1 mg/mL), or the F(ab) fragment of IgA. Only IgA and
Comparison of the mesangial FcaR with FcaR1 (CD89)its Fc fragment were able to block binding of IgA-FITC,
with maximal inhibition occurring at 1 mg/mL of unla- Having established that HMCs express an IgA recep-
beled IgA and Fca fragment. The lack of inhibition with tor specific for the Fc portion of the IgA molecule, we
Asialofetuin (ASF) (1 mg/mL) excluded any significant wished to compare this receptor with the only other
interaction with an ASGPR. This binding profile was FcaR characterized in the literature, CD89. Interaction
found in all five primary mesangial cultures and sug- of IgA with CD89 is blocked by binding of My43 [51],
gested that the HMC receptor for IgA is class specific and we therefore attempted to reproduce this effect.
and dependent on the Fc portion of the IgA molecule. My43 was unable to inhibit binding of IgA to HMCs
In a further set of experiments, we performed compar- (Fig. 4A), despite an appropriate reduction in binding
of IgA to PMA-activated U937 cells (Fig. 4B). This lackative studies of the ability of different human IgA iso-
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Fig. 4. My43 mediated inhibition of IgA binding to HMC (A) and
PMA-activated U937 cells (B). Cells were washed at 48C and IgA (50
mg/mL) binding assessed after a 45-minute incubation with either My43
or P/B/A. Viable cells were analyzed for IgA binding by flow cytometry,
as described in the Methods section. In both panels, the shaded area
represents the autofluorescence of U937 or HMCs, and the overlaid
histograms correspond to the IgA binding obtained following incubation Fig. 5. Detection of CD89 protein synthesis by HMCs. (A) Mesangial
with either My43 or P/B/A. My43 was unable to inhibit IgA binding cells were stained for cell surface expression of CD89 ( ), and intracel-
to HMCs; in contrast, there was a marked reduction in binding of lular flow cytometry was performed to identify cytoplasmic CD89 (j).
IgA to PMA-activated U937 cells following preincubation with My43. Cell surface expression of HLA class I and intracellular staining with
Identical results were obtained when HMCs from each of the other an antinucleus antibody (ANA) were used as positive controls. The
primary mesangial cultures were used. results shown are MCF 6 SEM of five different experiments performed
on a single HMC line. At no time could we demonstrate the presence
of CD89 expression by HMCs, despite clear evidence of cell surface
and cytoplasmic staining for control proteins. Identical results were
obtained with all five primary HMC cultures. (B) For comparison, these
of inhibition was exhibited by all primary HMC cultures. experiments were repeated using PMA-activated U937 cells.
To investigate this further, we went on to determine
whether HMCs in vitro synthesize CD89 protein by look-
ing for expression of CD89 protein both on the cell positive both for cell surface and intracellular expression
surface and within the cytoplasm of HMCs. We were of the receptor (Fig. 5B). To ensure that the lack of
unable to demonstrate CD89 protein synthesis by any HMC staining for CD89 was not simply a reflection of
of the primary HMC cultures, despite positive staining the trypsinization process cleaving CD89 during HMC
for HLA class I and intracellular staining with antilacto- detachment, a nonproteolytic method of detachment em-
ferrin, antimitochondrial, antigolgi zone (data not shown), ploying EDTA alone was also used. This did not alter
and antinucleus antibodies (Fig. 5A). In contrast, stain- our findings, however, and staining for CD89 remained
negative (data not shown).ing for CD89 on PMA-activated U937 cells was strongly
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To confirm the absence of CD89 expression by HMCs
and to exclude the possibility that HMCs in vitro produce
a soluble CD89 variant, instead of the expected mem-
brane-bound form, Western blots of HMC lysates and
culture supernatants from all five primary cultures were
examined. Consistent with the flow cytometry data, we
were unable to detect HMC-associated CD89 protein,
while immunoblotting of HMC supernatant failed to
demonstrate the presence of a soluble CD89 isoform.
As expected, a broad band (50 to 70 kD) of reactivity
was seen when PMA-activated U937 cell lysate was im-
munoblotted and stained for CD89 (data not shown).
To ensure that the lack of HMC CD89 expression was
not due to the activation state of the cultured cells, HMCs
from each of the five primary lines were incubated for
72 hours with increasing concentrations of PMA, LPS,
IFN-g, TNF-a, or IL-6 before IgA binding and staining
for CD89 were assessed. Treatment of HMCs with each
of the test stimuli resulted in clear evidence of activation
with increased HLA class I expression and a reproduc-
ible increase in IgA binding and IFN-g also induced
HLA class II synthesis. However, we were again unable
to detect CD89 synthesis by HMCs (Fig. 6). SDS-PAGE
and immunoblotting of HMC lysates and supernatants
from activated HMC similarly failed to demonstrate
CD89 expression (data not shown).
Detection of CD89 mRNA by RT-PCR and
Northern blotting
Despite being unable to demonstrate HMC CD89 pro-
tein synthesis, previous studies had reported CD89
mRNA expression by HMCs [14, 34]. We therefore
looked for CD89 mRNA in quiescent and activated
HMCs by RT-PCR using the primers detailed in the
Methods section. The predicted PCR products were ob-
tained with only one of the nine primer combinations
(Fig. 7A), and this pattern was unaltered by HMC activa-
Fig. 6. Attempted induction of latent CD89 synthesis by HMCs. Mes-tion. By contrast, all nine primer pairings generated the
angial cells were rendered quiescent for 72 hours prior to being incu-
expected bands when RNA from PMA-activated U937 bated for 48 hours with increasing concentrations of PMA, LPS, IFN-g,
TNF-a, or IL-6. IgA binding (A) and CD89 (combined cell surface andcells was used in parallel (Fig. 7B). To confirm the iden-
cytoplasmic) expression (B) were then measured by flow cytometry.tity of the various PCR products generated, the major
To demonstrate adequate mesangial activation, staining for HLA classes
band and selected minor bands for each primer combina- I and II was also performed. In this experiment, HMCs were incubated
with IFN-g (5 ng/mL) and IgA binding (.), and induction of CD89 ortion were sequenced. For PMA-activated U937 cells, the
HLA staining (j in panel B) was measured. These have been comparedsequences obtained were identical to the published CD89
with the IgA binding (j in panel A) and cell surface staining ( )
sequence and corresponded to the presence of wild-type observed in quiescent HMCs. The results shown are means 6 SEM of
three different experiments performed in triplicate on a single HMC(WT) receptor and the D66EC2, DS266EC2, DEC2, and
line. Activation resulted in enhanced IgA binding by HMC and up-DS2EC1 splice variants [52]. Despite generating PCR
regulation in HLA class I expression with induction of HLA class II
product with only one primer pairing (#3 and #4), the synthesis; however, we were still unable to detect CD89 synthesis by
HMCs. Similar results were obtained with PMA, LPS, TNF-a, and IL-6.sequences of the HMC-derived bands were identical to
those expected with these primers for WT and D66EC2
and DEC2 splice variants. However, the absence of prod- require further investigation. Finally, we were unable to
uct with the other eight primer pairings clearly distin- detect expression of the FcaRb isoform of CD89 in any
guished these HMC transcripts from those detected in of the HMC cultures or in PMA-activated U937 cells.
PMA-activated U937 cells (Fig. 8). The exact nature To confirm the results obtained by RT-PCR and as
an initial attempt to examine the relevance of these noveland importance of these novel CD89-related transcripts
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were always seen with PMA-activated U937 cells (Fig.
9). Equal loading of the gel was confirmed by rehybrid-
ization of the blot for the housekeeping gene cyclophilin.
Cyclophilin expression was unaffected by pretreatment
of HMC in an attempt to induce IgA receptor expression
(data not shown).
DISCUSSION
The reasons for mesangial IgA deposition and pro-
gressive glomerular injury in IgAN remain unknown.
MC proliferation and activation are clearly involved in
the pathogenenic process, and therefore, attention has
focused on interactions between the IgA molecule and
the MC. Here, we report the characterization of an IgA
receptor expressed by HMCs.
The IgA receptor that we have identified is constitu-
tively expressed by HMCs and binds the Fc portion of
IgA in an isotype-specific, dose-dependent, and satura-
ble manner. The identified FcaR was able to bind both
serum and secretory IgA equally and did not distinguish
between IgA1 and IgA2 subclasses. mIgA appeared to
bind with lower affinity than pIgA, although formal bind-
ing affinity measurements await isolation of the receptor.
IgA binding could not be blocked with asialofetuin, a
glycoprotein with extremely high affinity for the hepatic
ASGPR, demonstrating that this receptor was not a mes-
angial ASGPR, although this finding does not exclude
the possibility of coexpression of an ASGPR by HMCs,
as the IgA used in these binding studies was normally
sialyated and therefore not a favorable ligand for an
ASGPR.
There is some confusion surrounding the relationship
of the mesangial IgA receptor to the myeloid FcaR
CD89. Initial reports suggested that MC expressed CD89
[14, 34] and that this was the mesangial IgA receptor in
question. This was supported in another study in which
investigators reported increased CD89 mRNA expres-Fig. 7. Agarose gel electrophoresis of RT-PCR products derived from
sion in renal biopsy specimens and isolated glomeruli ofHMC (A) and PMA-activated U937 cells (B). cDNA were synthesized
using AMV reverse transcriptase, followed by 30 cycles of amplification patients with IgAN [35]. However, none of these studies
with Taq DNA polymerase using nine different human FcaR1-specific demonstrated the expression of functional receptor, butprimer combinations: lane 1 (#1/#6), 2 (#2/#5), 3 (#3/#4), 4 (#2/#6), 5
instead relied on the identification of CD89 mRNA with(#2/#4), 6 (#3/#6), 7 (#3/#5), 8 (#1/#5), and 9 (#1/#4; A, upper panels)
and GAPDH primers (B, lower panels). Only one primer pairing (#3/ RT-PCR or Northern blotting. A study using immuno-
#4) generated the expected PCR product in HMCs, while all nine primer histochemistry with the anti-CD89 MoAb My43 failedcombinations generated the expected bands when RNA from PMA-
to reveal glomerular expression of CD89 protein despiteactivated U937 cells was used. This pattern of mRNA expression was
consistent across each of the five primary HMC lines and did not change readily detectable CD89 mRNA [35], and recent studies
following mesangial activation. have demonstrated that HMCs can both bind and be
activated by IgA in the absence of detectable CD89
protein and mRNA [36, 54].
In agreement with these latter reports, we have failedtranscripts, Northern blot analysis was performed on the
to find evidence for cell surface or intracellular CD89RNA isolated from quiescent and activated HMCs using
expression by HMCs with a panel of five anti-CD89a CD89 specific cDNA probe. We consistently failed to
MoAbs [51, 55]. In addition, we could not inhibit IgAdetect any homologous transcripts in HMCs, while on
binding to the mesangial FcaR with My43, a MoAbthe same blots, two major CD89 hybridizing transcripts
of 2.8 and 2.6 kb, as has previously been described [53], that has been shown to specifically block IgA binding
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Fig. 8. Diagrammatic representation of the FcaR1 mRNA transcripts detected in HMCs (A) and PMA-activated U937 cells (B). The upper panel
represents wild-type (WT) FcaR1 transcript with the position of the six primers used in the PCR indicated by arrows. The three transcripts detected
in HMCs exhibited partial identity with those found in PMA-activated U937 cells, although there were marked differences in both the 59 and 39
coding sequences as no PCR product could be generated when primers #1, #2, #5, and #6 were used.
to CD89 [51]. Immunoglobulin Fc receptors can also ing. It has been postulated for some time that, like other
classes of Fc receptors, multiple Fca receptors exist.exist as functionally important soluble proteins [56–58],
but we failed to find evidence for CD89 secretion by in Lymphocytes and the myelomonocytic cell line THP-1
are both known to bind IgA in an Fca-dependent mannerHMC culture supernatants. Stimulation of HMCs with
PMA, LPS, IFN-g, IL-6, and TNF-a did not induce CD89 in the absence of CD89 [27, 59], although the FcaRs
involved have not yet been isolated. The nature of theseexpression in any form, despite clear evidence of HMC
activation and enhanced IgA binding, and therefore, we receptors and their relationship to CD89 are not clear.
However, the expression of novel CD89-related mRNAconclude that mesangial IgA binding is via a novel FcaR
and not CD89. transcripts by HMCs may help explain the origins of
the mesangial FcaR. In contrast to previously publishedThe presence of a novel FcaR is perhaps not surpris-
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[31, 60–62]. These varied forms of CD89 have been
shown to have altered function [31, 60] and are recog-
nized differently by the five MoAbs that bind CD89
[55, 63]. Unfortunately, to date, no proteins correspond-
ing to the multiple CD89 splice variants reported have
been identified in vivo, and most attempts at cloning
and expressing these variants have proved unsuccessful.
Interestingly, in the only published report to date in which
this has been accomplished, the expressed splice variant
had a very different affinity for IgA when compared with
WT receptor and was poorly recognized by all of the
anti-CD89 MoAbs [64]. Therefore, it is conceivable that
HMCs express truncated CD89 proteins that retain the
ability to bind IgA but have lost the epitopes recognized
by the MoAbs used to detect CD89 expression.
Alternatively, the transcript fragments we have identi-
fied may encode a completely new protein with partialFig. 9. Northern blot analysis of CD89 mRNA (upper panel) expres-
sion by PMA-activated U937 cells and HMC cultured in medium alone homology to CD89. This hypothesis originates from the
(lane A), or in the presence of PMA (1027 mol/L; lane B), LPS (1 mg/mL; recent discovery of a group of genes mapping to chromo-
lane C), IFN-g (5 ng/mL; lane D), TNF-a (5 ng/mL; lane E) or IL-6
some 19q13.4 and encoding a family of type I transmem-(100 U/mL; lane F). For these experiments, HMCs were allowed to
grow to confluence and then rendered quiescent for 72 hours prior to brane proteins with significant homology: FcaR1 (CD89),
incubation for 24 hours in test medium. The same blot was stripped paired Ig-like receptors (PIRs), killer inhibitory recep-
and rehybridized with a cyclophilin-specific cDNA probe, to show equiv-
tors (KIRs), leukocyte Ig-like receptor (LIRs), and Ig-likealent RNA loading (lower panel). We were unable to demonstrate the
presence of any homologous transcripts in HMCs; however, two CD89 transcripts (ILTs) [65]. Homology is most pronounced
hybridizing transcripts of 2.8 kb and 2.6 kb were consistently observed in the extracellular domains of the respective proteins
with PMA-activated U937 cells.
with PIR-A, exhibiting up to 50% homology with CD89
[66], while the Ig-like domains of KIR proteins have
between 35 and 45% identity with the extracellular do-
mains of CD89 [67]. Furthermore, each of these receptorreports [14, 34, 36, 54], three different mRNA transcripts
were identified consistently in all five primary HMC cul- subfamilies contain an ever increasing number of highly
homologous, but functionally distinct proteins. Over 20tures, and while these exhibited partial identity to WT
receptor and the D66EC2 and DEC2 splice variants, there different KIR sequences have been identified thus far
[68]. It has also been demonstrated for a number of thesewere clear differences in the 59- and 39-flanking se-
quences. Indeed, the differences were extensive enough subfamilies that the receptors exist in two forms, one of
which has a long cytoplasmic domain containing one toto prevent four of the six CD89 primers from annealing
to the HMC transcripts and generating PCR product. four immunoreceptor tyrosine-based inhibitory motifs
(ITIM) and another form with a short cytoplasmic tailWhile Northern blotting with a CD89 probe failed to
detect homologous mRNA in quiescent and activated without ITIMs. This latter form often has a positively
charged Arg residue within the transmembrane regionHMCs, this does not necessarily mean that these tran-
scripts are functionally unimportant. Their presence in of the receptor allowing interaction with the common
FcR g chain, which contains an immunoreceptor tyro-low copy number and the lack of complete identity with
the probe used could explain our failure to detect them sine-based activation motif (ITAM), to form a signal
transducing unit [68]. The ITIM-containing receptorsby Northern blotting. Furthermore, it is a well-recog-
nized phenomenon that while multiple transcripts of a will therefore recruit cytoplasmic tyrosine phosphatases
and provide inhibitory signals for cell activation, whereasgiven gene may be detectable by RT-PCR, not all can
be demonstrated when the same RNA is analyzed by receptors with a “short tail” will induce activating signals
by interacting with the ITAM-containing FcR g chain.Northern blotting. Although we have no direct evidence
to link these novel transcripts with the mesangial FcaR, From the existence of so many homologous receptors,
it does not seem unreasonable to suppose that FcaR1there are a number of intriguing possibilities.
These transcripts may in fact be markedly truncated might also be part of a divergent subfamily with multiple
members and varied patterns of expression. Perhapssplice variants of FcaR1 that encode functionally distinct
CD89 proteins with altered immunogenicity and IgA even more intriguing is the possibility that FcaR1 exists
in two forms with different signaling capabilities. At pres-binding. Heterogeneity of the CD89 molecule, princi-
pally caused by differential O- and N-linked glycosyla- ent, only the “short-tail” version has been described;
however, a novel variant with an extended transmem-tion, has been reported both in health [55] and disease
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